SH-4-54 - CAS 1456632-40-8
Catalog number: B0084-463434
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
SH-4-54 is a potent STAT inhibitor with KD of 300 nM and 464 nM for STAT3 and STAT5, respectively.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-463434 100 mg $499 In stock
Bulk Inquiry
Canonical SMILES:
1.Luteolin-Mediated Inhibition of Hepatic Stellate Cell Activation via Suppression of the STAT3 Pathway.
Cummins CB;Wang X;Nunez Lopez O;Graham G;Tie HY;Zhou J;Radhakrishnan RS Int J Mol Sci. 2018 May 24;19(6). pii: E1567. doi: 10.3390/ijms19061567.
Hepatic stellate cell (HSC) activation is responsible for hepatic fibrogenesis and is associated with an overexpression of transcription 3 (STAT3). Luteolin, a common dietary flavonoid with potent anti-inflammatory properties, has previously demonstrated antifibrogenic properties in HSCs but the mechanism has not been fully elucidated. Activated human and rat hepatic stellate cell lines LX-2 and HSC-T6 were used to study the effects of luteolin on HSCs. Cellular proteins were determined by western blot and immunofluorescence. Cell proliferation was assessed with Alamar Blue assay. Luteolin significantly decreased LX-2 and HSC-T6 cell viability in a time-and-dose-dependent manner, as well as decreased HSC end-products α-smooth muscle actin (α-SMA), collagen I, and fibronectin. Luteolin decreased levels of total and phosphorylated STAT3, suppressed STAT3 nuclear translocation and transcriptional activity, and attenuated expression of STAT3-regulated proteins c-myc and cyclin D1. STAT3 specific inhibitors stattic and SH-4-54 demonstrated similar effects on HSC viability and α-SMA production. In LX-2 and HSC-T6 cells, luteolin demonstrates a potent ability to inhibit hepatic fibrogenesis via suppression of the STAT3 pathway.
2.Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
Linher-Melville K;Nashed MG;Ungard RG;Haftchenary S;Rosa DA;Gunning PT;Singh G PLoS One. 2016 Aug 11;11(8):e0161202. doi: 10.1371/journal.pone.0161202. eCollection 2016.
Pharmacologically targeting activated STAT3 and/or STAT5 has been an active area of cancer research. The cystine/glutamate antiporter, system xc-, contributes to redox balance and export of intracellularly produced glutamate in response to up-regulated glutaminolysis in cancer cells. We have previously shown that blocking STAT3/5 using the small molecule inhibitor, SH-4-54, which targets the SH2 domains of both proteins, increases xCT expression, thereby increasing system xc- activity in human breast cancer cells. The current investigation demonstrates that chronic SH-4-54 administration, followed by clonal selection of treatment-resistant MDA-MB-231 and T47D breast cancer cells, elicits distinct subtype-dependent effects. xCT mRNA and protein levels, glutamate release, and cystine uptake are decreased relative to untreated passage-matched controls in triple-negative MDA-MB-231 cells, with the inverse occurring in estrogen-responsive T47D cells. This "ying-yang" effect is linked with a shifted balance between the phosphorylation status of STAT3 and STAT5, intracellular ROS levels, and STAT5 SUMOylation/de-SUMOylation. STAT5 emerged as a definitive negative regulator of xCT at the transcriptional level, while STAT3 activation is coupled with increased system xc- activity.
3.Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors.
Swerev TM;Wirth T;Ushmorov A Int J Oncol. 2017 Feb;50(2):555-566. doi: 10.3892/ijo.2016.3827. Epub 2016 Dec 30.
DNA methylation is an epigenetic control mechanism that contributes to the specific phenotype and to the oncogenic program of virtually all tumor entities. Although efficacy of demethylating agents in classical Hodgkin lymphoma (cHL) was not specifically tested, a case of regression of relapsed metastatic cHL was described as a fortunate side‑effect of the demethylating agent 5‑azacytidine in a patient with myelodysplastic syndrome. We investigated molecular mechanisms of decitabine (5‑Aza‑dC) antitumor activity in cHL using gene expression profiling followed by gene set enrichment analysis. We found that 5‑Aza‑dC inhibits growth of cHL cell lines at clinically relevant concentrations of 0.25‑2 µM. The antitumor effect of 5‑Aza‑dC was associated with induction of genes, which negatively regulate cell cycle progression (e.g. CDKN1A and GADD45A). Surprisingly, we also observed significant enrichment of pro‑survival pathways like MEK/ERK, JAK‑STAT and NF‑κB, as well as signatures comprising transcription‑activating genes. Among the upregulated pro‑survival genes were the anti‑apoptotic genes BCL2 and BCL2L1, as well as genes involved in transduction of growth and survival signals like STAT1, TLR7, CD40 and IL-6.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related STAT Products

CAS 1456632-40-8 SH-4-54

(CAS: 1456632-40-8)

SH-4-54 is a potent STAT inhibitor with KD of 300 nM and 464 nM for STAT3 and STAT5, respectively.

CAS 1456632-41-9 SH5-07

(CAS: 1456632-41-9)

SH5-07 is a robust hydroxamic acid-based STAT3 inhibitor with an IC50 of 3.9±0.6 μM in in vitro assay, which induce antitumor cell effects in vitro and antitumo...

CAS 501919-59-1 S31-201

(CAS: 501919-59-1)

S31-201 is benezoic acid based small molecule, which inhibits the Stat3 transcription factor by blocking the phosphorylation and dimerization events necessary f...

CAS 919486-40-1 AS 1517499

AS 1517499
(CAS: 919486-40-1)

AS 1517499 is a potent and selective STAT6 inhibitor (IC50 = 21 nM).

CAS 965-52-6 Nifuroxazide

(CAS: 965-52-6)

Nifuroxazide is a cell-permeable and orally available nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 tran...

CAS 35825-57-1 Cryptotanshinone

(CAS: 35825-57-1)

Cryptotanshinone, a natural cell-permeable diterpene quinone isolated from Salvia miltiorrhiza, it inhibits acetylcholinesterase (IC50 = 4.09 μM) and reduces Aβ...

(CAS: 725233-55-6)

ISS610 is a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Reported has shown that aberrant activation of oncogenic signal transducer and...

CAS 285986-31-4 STAT5-IN-1

(CAS: 285986-31-4)

STAT5-IN-1, a cell-permeable nonpeptidic nicotinoyl hydrazone compound, is a selective STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform with much less e...

CAS 546-43-0 Alantolactone

(CAS: 546-43-0)

Alantolactone is sesquiterpene lactone, significantly reduces feeding and survival of Tribolium confusum.

Corylifol A
(CAS: 775351-88-7)

Corylifol A is extracted from the seeds of Psoralea corylifolia L and belongs to phenolic compounds. It inhibits IL-6-induced STAT3 promoter activity in Hep3B c...

CAS 328998-53-4 inS3-54A18

(CAS: 328998-53-4)

inS3-54A18 is a potent inhibitor of the DNA-binding domain (DBD) of STAT3, with anti-cancer properties.


APTSTAT3-9R is a specific STAT3-binding peptide with addition of a cell-penetrating motif. STAT3 has been reported to promote the proliferation, survival, metas...

CAS 1334493-07-0 BP-1-102

(CAS: 1334493-07-0)

BP-1-102 is a potent and selective STAT3 inhibitor. BP-1-102 inhibits the expression of genes including c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-l...

CAS 960201-81-4 SD 1008

SD 1008
(CAS: 960201-81-4)

SD 1008 is a JAK2/STAT3 signaling pathway inhibitor that inhibits activation of STAT3, JAK2 and Src. SD 1008 induces apoptosis in cell lines expressing constitu...

CAS 229305-39-9 Golotimod

(CAS: 229305-39-9)

Golotimod is an orally bioactive synthetic peptide containing the amino acids D-glutamine and L-tryptophan connected by a gamma-glutamyl linkage with potential ...

Chemical Structure

CAS 1456632-40-8 SH-4-54

Quick Inquiry

Verification code

Featured Items